SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Evaluating Drug Prices, Availability, Affordability, and Price Components: Implications for Access to Drugs in Malaysia
0 references·16 citing·34 second hop
Evaluating Drug Prices, Availability, Affordability, and Price Components: Implications for Access to Drugs in Malaysia (2007)Evaluating Drug Prices, Availability, Aff…The Availability, Pricing, and Affordability of Essential Diabetes Medicines in 17 Low-, Middle-, and High-Income Countries (2019)The Availability, Pricing, an…The availability, prices and affordability of essential medicines in Malawi: A cross-sectional study (2019)The availability, prices and …Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology (2019)Evaluation of prices, availab…Evaluating medicine prices, availability and affordability in Bangladesh using World Health Organisation and Health Action International methodology (2019)Evaluating medicine prices, a…Oromia Bölgesel Devleti Doğu Shewa, Etiyopya’daki sağlık tesislerinde en önemli temel ilaçların envanter yönetimi performansı (2017)Oromia Bölgesel Devleti Doğu …Cost of hospitalization for childbirth in India: how equitable it is in the post-NRHM era? (2017)Cost of hospitalization for c…Cost of hospitalisation for non‐communicable diseases in India: are we pro‐poor? (2016)Cost of hospitalisation for n…Availability of medicines in public sector health facilities of two North Indian States (2015)Availability of medicines in …Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all (2013)Where are we now: assessing t…The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use (2013)The experiences of implementi…The Availability, Pricing and Affordability of Three Essential Asthma Medicines in 52 Low- and Middle-Income Countries (2013)The Availability, Pricing and…Switching from Originator Brand Medicines to Generic Equivalents in Selected Developing Countries: How Much Could Be Saved? (2012)Switching from Originator Bra…Is the Brazilian pharmaceutical policy ensuring population access to essential medicines? (2012)Is the Brazilian pharmaceutic…Management of intellectual property rights in India: An updated review (2011)Management of intellectual pr…Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries (2011)Differences in the availabili…Trade, TRIPS, and pharmaceuticals (2009)Trade, TRIPS, and pharmaceuti…Qualitative Research Methods (2006)Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis (2008)Qualitative Research Methods (2021)Medicines and vaccines supply chains challenges in Nigeria: a scoping review (2022)Catastrophic payments for health care in Asia (2007)The availability and affordability of selected essential medicines for chronicl diseases in six low- and middle-income countries (2007)Essential Medicines Are More Available than Other Medicines around the Globe (2014)Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018)European Healthcare Policies for Controlling Drug Expenditure (2003)The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending (2003)Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? (2014)The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians (2015)Household catastrophic health expenditure: a multicountry analysis (2003)Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries (2016)Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseases (2017)World Health Forum (1981)Defending Interests: Public-Private Partnerships in WTO Litigation (2004)Trade and health: an agenda for action (2009)Advancing health equity in the global marketplace: How human rights can help (2010)Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis (2012)Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the Developing World (2010)THE WORLD MEDICINES SITUATION 2011 (2011)Better Health Systems for India's Poor : Findings, Analysis, and Options (2002)Cost of delivering secondary-level health care services through public sector district hospitals in India (2017)Cost of Intensive Care Treatment for Liver Disorders at Tertiary Care Level in India (2017)Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data (2010)Of markets and rights: Discourse in the 2008 and 2013 Global Action Plan for the Prevention and Control of Noncommunicable Diseases (2016)Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2014)Global, regional, and national age–sex specifi c all-cause andcause-specifi c mortality for 240 causes of death, 1990–2013:a systematic analysis for the Global Burden of DiseaseStudy 2013 (2015)Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications (2020)Financial risk protection against noncommunicable diseases: trends and patterns in Bangladesh (2022)Rural‒urban disparities in household catastrophic health expenditure in Bangladesh: a multivariate decomposition analysis (2024)Projections of Global Mortality and Burden of Disease from 2002 to 2030 (2006)Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure (2021)
this work references cited by second hop

References

No references inside the corpus for this window.

Cited by

  • 2011Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries187 cited
  • 2012Switching from Originator Brand Medicines to Generic Equivalents in Selected Developing Countries: How Much Could Be Saved?178 cited
  • 2009Trade, TRIPS, and pharmaceuticals175 cited
  • 2013The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use159 cited
  • 2013The Availability, Pricing and Affordability of Three Essential Asthma Medicines in 52 Low- and Middle-Income Countries135 cited
  • 2015Availability of medicines in public sector health facilities of two North Indian States122 cited
  • 2019The Availability, Pricing, and Affordability of Essential Diabetes Medicines in 17 Low-, Middle-, and High-Income Countries90 cited
  • 2019Evaluating medicine prices, availability and affordability in Bangladesh using World Health Organisation and Health Action International methodology86 cited
  • 2012Is the Brazilian pharmaceutical policy ensuring population access to essential medicines?80 cited
  • 2019The availability, prices and affordability of essential medicines in Malawi: A cross-sectional study79 cited
  • 2019Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology75 cited
  • 2013Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

69 cited
  • 2016Cost of hospitalisation for non‐communicable diseases in India: are we pro‐poor?48 cited
  • 2017Cost of hospitalization for childbirth in India: how equitable it is in the post-NRHM era?24 cited
  • 2017Oromia Bölgesel Devleti Doğu Shewa, Etiyopya’daki sağlık tesislerinde en önemli temel ilaçların envanter yönetimi performansı23 cited
  • 2011Management of intellectual property rights in India: An updated review15 cited